On Friday, Shares of Inotek Pharmaceuticals Corporation (NASDAQ:ITEK), surged 14.83% to $17.65, hitting its highest level.
Inotek Pharmaceuticals Corporation declared the appointment of ophthalmic drug development expert, Cadmus Collins Rich, MD, MBA, CPE, as Vice President, Medical Affairs and Clinical Development. Most recently, Dr. Rich served as a Therapeutic Unit Head at Alcon for intraocular lenses. Preceding to this he was the Global Head, Pharmaceutical Clinical Trial Administration at Alcon, where he led a team of 25-plus MDs and PhDs and shepherded the submission and approval of Nevanac®, Durezol®, and Izba®, and the recently approved glaucoma treatment, Simbrinza®. In his role, Dr. Rich will report to Rudolf Baumgartner, M.D, Chief Medical Officer of Inotek.
“We are happy to welcome Dr. Rich to Inotek. He brings to the company a wealth of experience as a practicing ophthalmologist and as a seasoned clinical developer focused on ophthalmology having worked both in Specialty Pharma and in a Contract Research Organization,” said Dr. Rudolf Baumgartner, Chief Medical Officer. “Dr. Rich’s clinical development experience will be important to us as we progress trabodenoson through clinical trials, and build our portfolio. We will also benefit from his years as a practicing ophthalmologist and the respect he has earned among a network of medical and scientific specialists focused on ophthalmology. We look forward to his contributions as we grow our company and advance trabodenoson towards an NDA.”
Inotek Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for glaucoma.
Shares of Tidewater Inc. (NYSE:TDW), declined -1.63% to $19.27, during its last trading session.
Tidewater declared that its fiscal 2016 first quarter (ended June 30, 2015) earnings conference call has been planned for Tuesday, August 11, 2015 at 10:00 a.m. Central time. During the conference call, the Company will talk about the results for the quarter ended June 30, 2015, which are predictable to be released on August 10, 2015, after the markets close.
Tidewater Inc. provides offshore service vessels and marine support services through the operation of a fleet of marine service vessels to the offshore energy industry worldwide. The company operates in Americas, Asia/Pacific, Middle East/North Africa, and Sub-Saharan Africa/Europe segments.
Finally, Quest Diagnostics Inc. (NYSE:DGX), ended its last trade with -1.38% loss, and closed at $73.37.
Quest Diagnostics Incorporated declared that for the second quarter ended June 30, 2015, adjusted net income was $170 million contrast to $157 million for 2014. Adjusted diluted EPS not taking into account amortization was $1.25 in the second quarter of 2015, contrast to $1.19 in 2014. Amortization expense per diluted share was $0.08 in the second quarter of 2015 and $0.11 in 2014.
For the second quarter of 2015, stated net income was $118 million, or $0.81 per diluted share, contrast to $133 million, or $0.92 per diluted share, in 2014. Stated net income in the second quarter of 2015 was negatively influenced by charges of $52 million after tax, or $0.36 per diluted share, of which $41 million is associated with the company’s recent debt refinancing. The remainder of the charges were related to restructuring and integration costs and ongoing efforts to drive operational excellence. In the second quarter of 2014, stated net income was reduced by charges of $24 million after tax, or $0.16 per diluted share, primarily related to restructuring and integration costs associated with acquisitions and ongoing efforts to drive operational excellence.
Second quarter 2015 revenue of $1.93 billion grew by 1.2% as compared to the preceding year and grew 0.8% on an organic basis. Diagnostic information services revenue grew by 0.4%. Volume, measured by the number of requisitions, reduced by about 0.4%. Revenue per requisition grew by about 0.9%.
Quest Diagnostics Incorporated provides diagnostic testing information services in the United States and internationally. The company offers clinical testing services, such as routine testing, gene-based and esoteric testing, anatomic pathology services, and drugs-of-abuse testing, in addition to related services and insights; laboratory testing services for new drugs, vaccines, and medical devices; analytic, on-site prevention, and wellness services; and risk assessment services for the life insurance industry.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
